Ameritas Investment Partners’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Ameritas Investment Partners’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-436	Closed	-$11K	–	3325
2021 Q1	$11K	Hold	436	–	–	﹤0.01%	2835
2020 Q4	$16K	Hold	436	–	–	﹤0.01%	2598
2020 Q3	$15K	Buy	436 +276	+173%	+$12K	﹤0.01%	2546
2020 Q2	$7K	Buy	160 +77	+93%	+$5.19K	﹤0.01%	2900
2020 Q1	$7K	Hold	83	–	–	﹤0.01%	2724
2019 Q4	$8K	Hold	83	–	–	﹤0.01%	2823
2019 Q3	$6K	Hold	83	–	–	﹤0.01%	2915
2019 Q2	$8K	Buy	+83	New	+$6.43K	﹤0.01%	2874

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Ameritas Investment Partners's EVFM Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 436 shares — an estimated $11K sold.

Ameritas Investment Partners first reported a position in EVFM in Q2 2019 and held it in 8 quarters. The position peaked at $16K in Q4 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Ameritas Investment Partners reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Partners sold 436 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $11K.
Ameritas Investment Partners first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Ameritas Investment Partners's Evofem Biosciences, Inc. Common Stock position peaked at $16K in Q4 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.